NBIX

#760
Neurocrine Biosciences Inc
130.8100 USD
+3.55%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
130.8100
130.8100
1年のレンジ
122.1375
160.1800
1日の変化
+3.55%
月次変化
+0.31%
6か月変化
-9.79%
1年の変化
-9.79%
以前の終値
126.3200
始値
130.8100
Bid
Ask
安値
130.8100
High
130.8100
ボリューム
127
チャート全体を表示

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 13.1285 B
  • Employee 2 000
  • Founded 1992
  • CEO Kevin C. Gorman
  • Website www.neurocrine.com
  • Headquarter Delaware, United States
  • FIGI BBG000GJS7C1
  • Industry Technology
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
30.37
売上高対価格比率
5.08

Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

ニュース